Skip to main content

Advertisement

Table 1 Demographics of respondents in each country (N = 15 per country)

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

  France Germany Italy Spain UK Total
  N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
Speciality, n (%)
 Oncologist 5 (33) 1 (7) 3 (20) 0 (0) 0 (0) 9 (12)
 Haematologist 5 (33) 2 (13) 7 (47) 8 (53) 8 (53) 30 (40)
 Haemato-oncologist 5 (33) 12 (80) 5 (33) 7 (47) 7 (47) 36 (48)
Location, n (%)
 University hospital 7 (47) 10 (67) 7 (47) 13 (86) 11 (73) 48 (64)
 Cancer hospital/specialist centre 6 (40) 4 (27) 5 (33) 0 (0) 2 (13) 17 (23)
 Community/urban/general hospital 2 (13) 1 (7) 3 (20) 2 (13) 2 (13) 10 (13)
Experience, years
 Years treating adults with ALL, median (range) 15 (7–29) 12 (8–18) 10 (6–30) 16 (9–34) 12 (17–20) N/A
Caseloada of ALL subtypes from 12 months before the survey, n
 ALL, median (range) 30 (3–200) 20 (6–100) 30 (5–100) 20 (3–230) 24 (4–200) N/A
 R/R Ph(–) B-precursor ALL, median (range) 8 (1–75) 3 (1–21) 5 (1–50) 4 (0–55) 4 (1–50) N/A
  1. aNumber of patients
  2. ALL acute lymphoblastic leukaemia, N/A not available, Ph(–) Philadelphia negative, R/R relapsed or refractory